Table 1.
Baseline characteristics between control and study group (mean ± SD)
| Parameter | Control group (n = 23) | Study group (n = 22) | P value |
| Age (yr) | 47.35 ± 12.54 | 48.91 ± 9.25 | 0.64 |
| Sex ratio (M:F) | 20:3 | 16:6 | 0.072 |
| Hemoglobin (g/dL) | 9.29 ± 1.86 | 9.15 ± 1.60 | 0.79 |
| Platelet count (Lakhs/mm3) | 0.92 ± 0.27 | 1.1 ± 0.72 | 0.24 |
| Total bilirubin (mg/dL) | 4.78 ± 4.06 | 3.55 ± 2.12 | 0.21 |
| AST (IU/mL) | 101.61 ± 174.41 | 67.14 ± 55.99 | 0.30 |
| ALT (IU/mL) | 77.87 ± 125.54 | 32.45 ± 17.07 | 0.10 |
| Albumin (mg/dL) | 2.7 ± 0.35 | 2.55 ± 0.35 | 0.16 |
| INR | 1.72 ± 0.53 | 1.80 ± 0.52 | 0.62 |
| Creatinine (mg/dL) | 1.08 ± 0.38 | 1.02 ± 0.29 | 0.56 |
| MELD score | 18.73 ± 5.29 | 18.28 ± 3.50 | 0.74 |
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; IU: International unit; INR: International normalized ratio; MELD: Model for end-stage liver disease score.